Updates are available Correction dated 2025-05-27
Click to view Correction: https://doi.org/10.1007/s00259-025-07344-6
-
Authors
Gaze, Mark N. https://orcid.org/0000-0002-8344-7902
Handkiewicz-Junak, Daria https://orcid.org/0000-0003-0802-2880
Hladun, Raquel
Laetsch, Theodore W. https://orcid.org/0000-0002-8497-3138
Sorge, Caryn
Sparks, Richard
Wan, Simon https://orcid.org/0000-0001-6831-1129
Ceraulo, Antony https://orcid.org/0000-0002-4995-1494
Kluczewska-Galka, Aneta
Gámez-Cenzano, Cristina https://orcid.org/0000-0003-3562-8423
States, Lisa J. https://orcid.org/0000-0003-0260-3975
El Khouli, Riham
Aimone, Paola
Perraud, Kevin
Kollar, Gabor https://orcid.org/0000-0003-1456-4520
Khanshan, Fariba
Blumenstein, Lars
Brouri, Fazia
Giraudet, Anne-Laure https://orcid.org/0000-0002-5366-1254
-
Funding
Funding for this research was provided by:
Advanced Accelerator Applications, a Novartis Company (Advanced Accelerator Applications, a Novartis Company)
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 24 March 2025
First Online: 8 April 2025
Change Date: 27 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00259-025-07344-6
Declarations
:
: The trial was performed in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines and all applicable regulations. This study was approved by the institutional review board or independent ethics committee at each participating centre (France: Comité de Protection des Personnes Ile-de-France; Poland: Komisja Bioetyczna przy Centrum Onkologii Instytut im. M. Skłodowskiej Curie; Spain: CEIC Hospital General Universitario Gregorio Marañon; UK: London – Westminster Research Ethics Committee Health Research Authority; USA: Cincinnati Children’s Hospital Medical Center IRB, CHOP Committees for the Protection of Human Subjects and University of Kentucky IRB).
: Written informed consent was obtained from the parent/legal guardian for adolescents or adolescents signed assent along with parental/legal guardian consent or co-signed consent with parent/legal guardian in accordance with local regulations, prior to participation in the study.
: MNG, RH, CS, SW, AC, AK-G, CG-C, LJS and REK have no relevant competing interests to disclose. DH-J has received travel grants and lecture fees from Ipsen, Novartis and Sanofi, and has acted as a consultant and served on advisory boards for Novartis. TWL has received research funding from Bayer and Pfizer, and has acted as a consultant and served on advisory boards for Advanced Microbubbles, AI Therapeutics, Bayer, GSK, ITM Oncologics, Jazz Pharmaceuticals and Massive Bio. RS declares that Novartis paid CDE Dosimetry Services to perform the dosimetry analysis. PA is an employee of Novartis. KP and GK are employees of Advanced Accelerator Applications, a Novartis Company. FK was an employee of Novartis at the time of manuscript development. LB is an employee of and holds stock and share options in Novartis. FB is an employee of and holds share options in Advanced Accelerator Applications, a Novartis Company. A-LG has received lecture fees and consultancy fees from Advanced Accelerator Applications (a Novartis company) and Curium.
